Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8887MR)

This product GTTS-WQ8887MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8887MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ607MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ12113MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ11022MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ6167MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ8265MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ5698MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ6643MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ11757MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW